JNJ

225.54

-0.03%↓

UNH

370.35

+1.35%↑

TMO

465.79

-0.01%↓

ISRG

450.79

-1.5%↓

ABT

86.59

-2.53%↓

JNJ

225.54

-0.03%↓

UNH

370.35

+1.35%↑

TMO

465.79

-0.01%↓

ISRG

450.79

-1.5%↓

ABT

86.59

-2.53%↓

JNJ

225.54

-0.03%↓

UNH

370.35

+1.35%↑

TMO

465.79

-0.01%↓

ISRG

450.79

-1.5%↓

ABT

86.59

-2.53%↓

JNJ

225.54

-0.03%↓

UNH

370.35

+1.35%↑

TMO

465.79

-0.01%↓

ISRG

450.79

-1.5%↓

ABT

86.59

-2.53%↓

JNJ

225.54

-0.03%↓

UNH

370.35

+1.35%↑

TMO

465.79

-0.01%↓

ISRG

450.79

-1.5%↓

ABT

86.59

-2.53%↓

Home・Stock List・Incyte Corp

Search

Incyte Corp

Open

SectorHealthcare

97.31 0.44

Overview

Share price change

24h

Current

Min

96.42

Max

97.44

Key metrics
By Trading Economics
Income	-125M 299M
Sales	141M 1.5B
P/E Sector Avg	14.932 67.147
Profit margin	19.861
Employees	2,844
EBITDA	-92M 415M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+11.51% upside

Dividends
By Dow Jones
Next Earnings	28 Jul 2026

Market Stats
By TradingEconomics
Market Cap	-2.4B 19B
Previous open	96.87
Previous close	97.31

News Sentiment

By Acuity

32%

68%

110 / 347 Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

59.52 / 62.66 Support & Resistance

Incyte Corp Chart

Past performance is not a reliable indicator of future results.

Related News

4 May 2026, 22:17 UTC

Earnings

Australia's Westpac Lifts Dividend as 1st Half Profit Rises 2.7%

4 May 2026, 23:47 UTC

Earnings

Grab Holdings 1Q Adj EBITDA $154.0M Vs. $106.0M >GRAB

4 May 2026, 23:45 UTC

Earnings

Grab Holdings 1Q Rev $955.0M Vs. $773.0M >GRAB

4 May 2026, 23:45 UTC

Earnings

Grab Holdings 1Q Net $120.0M Vs. Net $10.0M >GRAB

4 May 2026, 23:40 UTC

Market Talk

Gold Steady Amid Likely Technical Recovery -- Market Talk

4 May 2026, 22:44 UTC

Acquisitions, Mergers, Takeovers

Regis: Jim Beyer To Be Chief Executive of Combined Company

4 May 2026, 22:43 UTC

Acquisitions, Mergers, Takeovers

Regis: Russell Clark To Be Nonexecutive Chairman of Combined Company

4 May 2026, 22:42 UTC

Acquisitions, Mergers, Takeovers

Regis: Companies Expect to Realize Over A$500 Million in Corporate Tax Benefits

4 May 2026, 22:42 UTC

Acquisitions, Mergers, Takeovers

Regis: Combined Company to Have Strong, Debt-Free Balance Sheet; Significant Cash Generation

4 May 2026, 22:41 UTC

Acquisitions, Mergers, Takeovers

Regis: Combined Company to Have Annual Production of More Than 700,000 Oz

4 May 2026, 22:41 UTC

Acquisitions, Mergers, Takeovers

Regis: Pro Forma Market Capitalization About A$10.7 Billion

4 May 2026, 22:40 UTC

Acquisitions, Mergers, Takeovers

Regis: Shareholders to Own About 51% of Combined Company

4 May 2026, 22:40 UTC

Acquisitions, Mergers, Takeovers

Regis: Board Unanimously Endorsed, Supported Deal

4 May 2026, 22:40 UTC

Acquisitions, Mergers, Takeovers

Regis: Deal Unanimously Recommended by Vault Board

4 May 2026, 22:39 UTC

Acquisitions, Mergers, Takeovers

Regis: Vault Shareholders to Receive 0.6947 New Shares in Regis For Each Vault One Held

4 May 2026, 22:38 UTC

Acquisitions, Mergers, Takeovers

Regis Resources to Acquire All Ordinary Shares in Vault

4 May 2026, 22:38 UTC

Acquisitions, Mergers, Takeovers

Regis Resources, Vault Minerals Agree to Merger of Equals

4 May 2026, 22:37 UTC

Earnings

Acquisitions, Mergers, Takeovers

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- 2nd Update

4 May 2026, 22:26 UTC

Earnings

Acquisitions, Mergers, Takeovers

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- Update

4 May 2026, 22:02 UTC

Earnings

Australia's Westpac Lifts Dividend as 1H Profit Rises 2.7%

4 May 2026, 22:00 UTC

Market Talk

BOC's Macklem: Conditions To Dictate Fuel-Price Response -- Market Talk

4 May 2026, 21:52 UTC

Earnings

Westpac 1H Net Profit Ex-Notable Items A$3.48B Vs. A$3.46B>WBC.AU

4 May 2026, 21:50 UTC

Earnings

Westpac: Some Sectors More Affected Than Others>WBC.AU

4 May 2026, 21:50 UTC

Earnings

Westpac: Economic Impact of Middle East Conflict to Continue Through Year>WBC.AU

4 May 2026, 21:49 UTC

Earnings

Westpac 1H Provision for Expected Credit Losses A$4.68B Vs. A$4.58B>WBC.AU

4 May 2026, 21:44 UTC

Earnings

Westpac 1H Australia Lending Up 8% on Year>WBC.AU

4 May 2026, 21:44 UTC

Earnings

Westpac 1H Australia Business Lending Up 16% on Year>WBC.AU

4 May 2026, 21:43 UTC

Earnings

Westpac 1H Core Net Interest Margin 1.78% Vs. 1.80%>WBC.AU

4 May 2026, 21:41 UTC

Earnings

Westpac 1H Australian Home Lending Up 7% on Year Excluding RAMS Portfolio>WBC.AU

4 May 2026, 21:40 UTC

Earnings

Westpac 1H Credit Impairment Charge 10 Bps of Average Loans Vs. 6 Bps>WBC.AU

Peer Comparison

Price change

Incyte Corp Forecast

Price Target

By TipRanks

11.51% upside

12 Months Forecast

Average 108.06 USD 11.51%

High 135 USD

Low 75 USD

Based on 19 Wall Street analysts offering 12 month price targets forIncyte Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

19 ratings

8

Buy

10

Hold

1

Sell

Based on 19 analysts giving stock ratings to Incyte Corp - Dist in the past 3 months.

Technical Score

By Trading Central

59.52 / 62.66Support & Resistance

Bullish events outweigh bearish events.

All events are bearish.

All events are bearish.

Sentiment

By Acuity

110 / 347 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation

Other stocks from the sector

JNJ

Johnson and Johnson

225.54

UNH

UnitedHealth Group Inc

370.35

TMO

Thermo Fisher Scientific Inc

465.79

ISRG

Intuitive Surgical Inc

450.79

ABT

Abbott Laboratories

86.59

Live chat